Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Lung Neoplasms 4Neoplasms 2Solid Tumors 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 2a 1Lymphoma, Large-Cell, Anaplastic 1Lung Diseases 1Genomic Instability 1Central Nervous System Neoplasms 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Bone Neoplasms 1Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer 1

Interventions

Cyclophosphamide 3Gemcitabine 2regorafenib 1liposomal doxorubicin 1lenvatinib 1fludarabine 1alectinib 1aldesleukin 1Weight-Bearing 1Taxes 1Surveys and Questionnaires 1Restraint, Physical 1Range of Motion, Articular 1Quality of Life 1Proton Therapy 1Platinum 1Paclitaxel 1Nivolumab 1Metastasectomy 1Masks 1Lomustine 1Irinotecan 1Ipilimumab 1Everolimus 1Etoposide 1Doxorubicin 1Data Collection 1Cisplatin 1Carboplatin 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bone Neoplasms × alectinib × 90 days × Clear all
NCT07560410 2026-05-11

Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)

China Medical University Hospital

Phase 1/2 Not yet recruiting
10 enrolled
Sarcoma

Bone Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡